Enzolytics Inc. (OTC:ENZC) Stock in Focus After Latest News
One of the companies that may come to the attention of investors this Friday morning is Enzolytics Inc. (OTC:ENZC). The company came into focus yesterday after its subsidiary, Biogenysis Inc., made a major new announcement.
On Thursday, Biogenysis announced that it had made progress in its Patent Cooperation Treaty (PCT) application pertaining to its inventions related to anti-SARS-CoV-2 monoclonal antibodies. It was revealed in the news release that the application had progressed to the filing stage of a United States National Stage Application with the United States Patent Officer. Additionally, a formal application had also been made to the European Patent Organization (EPO). By way of the EPO application, the PCT would get coverage in as many as 39 nations. Those 39 nations include all the nations in the European Union, the United Kingdom, and other member nations in Europe, as well as adjacent regions.
The pending applications from the company cover a total of 23 claims. In the news release published yesterday, it was revealed that Biogenysis had deployed artificial intelligence in the project and discovered as many as 1.9 million immutable conserved virus sites on the COVID-19 virus. The company managed to make the discovery through the analysis of 2.8 million SARS-CoV-2 isolates. The analysis helps in the identification of the conserved, critical, and conserved epitopes of the COVID-19 virus.
The sites that had been identified by Biogenysis are patentable, as claimed by the company, due to their unique specificity and the discovery that they are conserved in the COVID-19 virus. The discovery from the company was significant since it indicated that it was possible to bind the immutable conserved sites, which can help in the neutralization of the virus without the chance of the phenomenon called ‘virus escape’ owing to viral mutation.
On August 8, Enzolytics’ fully owned subsidiary unit, Virogenetics Inc., was in focus after it made a new announcement. The company announced at the time that it had been granted an export permit so that it could deliver the treatments that would be administered to HIV/AIDS volunteer patients.
At the time, it was announced that the treatments were going to be administered at Bukavu, DRC, HEAL Africa Hospitals, PRC, Panzi Hospital, and GOMA. The results from the pilot clinical trial that took place in Africa were going to be used by the company to develop the European Medicine Authority (EMA) clinical trials. The company noted that the EMA trials were expected to commence in late 2023 or early 2024.
Virogenetics also acknowledges the announcement made by Sagaliam Acquisition Corp. with regards to the latter’s notification to Continental Stock and Transfer Company. In the notification, Sagaliam revealed that it was going to exercise its option to extend the available time for the consummation of a business combination agreement by an additional month. The deadline sought by Sagaliam was August 23, 2023. Virogenetics noted that significant progress had been made regarding the combination agreement between the two entities.
